Comparative efficacy and safety of Chinese patent medicines of iron deficiency anemia during pregnancy: A network meta-analysis

Table 1 Basic characteristics of the included studies

Ref.	Sample size T/C	Age (yr)		Duration of pregnancy (wk)		Intervention measures		Course	Outcome indicators
		T	C	T	C	T	C
Peng et al[18]	40/40	27.8 ± 5.3	27.1 ± 4.4	21.2 ± 4.3	20.6 ± 4.0	SXB + OI	OI	3 months	①②③④⑥⑦
Hu et al[19]	40/40	33.15 ± 3.15	33.37 ± 3.42	24.26 ± 2.11	24.52 ± 2.23	SXB + OI	OI	8 wk	①②③④⑦
Bi et al[20]	50/50	29.15 ± 2.46	29.64 ± 2.37	22.34 ± 0.87	22.56 ± 0.93	SXB + OI	OI	1 month	①②③④⑤⑥⑦
Zhang[21]	60/60	30.7 ± 5.0	31.6 ± 4.5	22.2 ± 3.8	21.2 ± 3.1	SXB + OI	OI	4 wk	①③④⑥⑦
Wang et al[22]	60/60	28.4 ± 3.6	28.5 ± 3.5	24.6 ± 1.3	24.5 ± 1.2	SXB + OI	OI	4 wk	②③④⑤⑥⑦
Ke et al[23]	40/40	29.74 ± 1.99	30.26 ± 2.08	22.37 ± 2.14	22.56 ± 2.03	SXB + OI	OI	3 months	①②③④⑤⑦
Yang et al[24]	56/56	28.52 ± 3.46	28.69 ± 3.81	27.53 ± 3.62	27.59 ± 3.31	SXN + OI	OI	4 wk	①②③④⑤⑥⑦
Wu[25]	40/40	30.25 ± 5.36	31.16 ± 5.48	-		SXN + OI	OI	1 month	①②③⑤⑥⑦
Peng[26]	40/40	29.44 ± 3.18	30.25 ± 3.11	28.71 ± 4.12	27.63 ± 4.19	SXN + OI	OI	4 wk	④⑤⑦
Yang[27]	80/80	29.0 ± 4.5	28.7 ± 4.1	22.6 ± 2.4	22.7 ± 2.6	SXN + OI	OI	4 wk	①②③④⑤
Chen et al[28]	44/44	27.51 ± 3.69	27.59 ± 3.75	29.58 ± 1.27	29.64 ± 1.32	SXN + OI	OI	4 wk	②③⑤
Sun et al[29]	33/34	28.93 ± 3.86	29.01 ± 3.92	23.53 ± 3.47	23.61 ± 3.51	SXN + OI	OI	4 wk	①②③⑤⑥⑦
Liu et al[30]	60/61	26.85 ± 3.35	27.12 ± 3.51	22.91 ± 2.37	23.07 ± 2.49	SXN + OI	OI	4 wk	②③⑤⑥
Fu et al[31]	39/39	25.3 ± 5.9	25.8 ± 5.2	21.0 ± 4.8	21.3 ± 4.4	SXN + OI	OI	30 d	②③⑤⑥⑦
Jiao[32]	50/50	26.74 ± 2.59	26.52 ± 2.78	33.41 ± 2.77	31.82 ± 2.23	SXN + OI	OI	28 d	①②③⑤
Gu[33]	50/50	30.1 ± 2.3		28.3 ± 1.5		SXN + OI	OI	4 wk	①②③
Ruan et al[34]	100/100	26.52 ± 2.74	26.14 ± 2.76	32.41 ± 2.61	31.86 ± 2.17	SXN + OI	OI	28 d	①②③⑤⑥
Li et al[35]	40/40	27.5 ± 2.8	27.9 ± 3.1	22.4 ± 6.3	22.0 ± 5.9	SXN + OI	OI	1 month	③⑦
Ji[36]	64/56	28.56 ± 1.58	28.13 ± 2.17	-		SXN + OI	OI	4 wk	①⑦
Zhao[37]	40/40	29.0 ± 2.0	9.54 ± 1.5	21.0 ± 1.5	20.5 ± 2.0	SXN + OI	OI	1 month	①②③⑤
Liu et al[38]	50/48	26.44 ± 4.58	26.89 ± 4.62	22.86 ± 3.88	23.03 ± 3.94	SXN + OI	OI	4 wk	①②③④⑤⑥⑦
Yin[39]	85/85	28.03 ± 5.68	27.91 ± 5.73	22.74 ± 7.05	22.58 ± 6.37	SXN + OI	OI	4 wk	①②③⑤
Chen[40]	42/42	26.1 ± 3.2	25.2 ± 2.1	20.5 ± 2.5	19.4 ± 2.2	SXN + OI	OI	1 month	①②③⑤⑥⑦
Sheng[41]	45/45	30.66 ± 4.06	30.85 ± 4.11	20.15 ± 1.25	20.98 ± 1.22	YQWX + OI	OI	12 wk	①③④⑤⑥⑦
Yu et al[42]	45/45	29.34 ± 6.84	30.20 ± 7.21	21.16 ± 1.20	21.42 ± 1.26	YQWX + OI	OI	3 months	①②③④⑤⑥
He[43]	40/40	29.64 ± 7.84	30.11 ± 7.68	21.46 ± 1.39	21.52 ± 1.37	YQWX + OI	OI	3 months	①②③④⑤⑥⑦
Ren et al[44]	43/43	32.12 ± 4.06	32.54 ± 4.17	22.45 ± 10.24	22.14 ± 10.14	YQWX+OI	OI	12 wk	①②③④⑥⑦
Zhang[45]	35/35	27.73 ± 3.78	27.25 ± 3.21	22.24 ± 1.89	22.31 ± 1.42	JPSX + OI	OI	4 wk	①③⑦
Yi[46]	30/30	29.01 ± 6.65	29.45 ± 6.71	24.51 ± 5.09	24.65 ± 5.13	JPSX + OI	OI	4 wk	①⑦
Wu et al[47]	50/50	29.4 ± 6.2	29.2 ± 4.6	19.8 ± 3.5	20.2 ± 3.9	JPSX + OI	OI	4 wk	①②③④⑤⑥⑦
Wu[48]	43/43	32.56 ± 4.29	31.96 ± 4.32	23.52 ± 3.18	23.40 ± 3.30	JPSX + OI	OI	1 month	①②③⑥⑦
Liu et al[49]	45/45	30.41 ± 7.43	30.29 ± 7.54	25.13 ± 8.70	25.21 ± 8.64	JPSX + OI	OI	4 wk	①③⑤⑦
Li[50]	40/40	33.4 ± 6.6	31.2 ± 6.5	20.4 ± 1.4	20.2 ± 1.5	JPSX + OI	OI	30 d	①②③④⑥
Xu[51]	53/53	23.15 ± 2.68	23.12 ± 2.82	23～34	22～33	JPSX + OI	OI	1 month	①②③④⑦
Wu[52]	35/35	28.03 ± 2.36	27.12 ± 5.16	24.03 ± 2.60	23.42 ± 3.22	JPSX + OI	OI	1 month	④⑤
Sun et al[53]	82/82	26.84 ± 3.57	27.35 ± 3.03	18.43 ± 2.06	17.87 ± 1.59	JPSX + OI	OI	3 months	①②③④⑤⑦
Shi et al[54]	65/64	27.38 ± 6.02	26.87 ± 5.14	23.02 ± 2.40	22.41 ± 3.12	JPSX + OI	OI	4 wk	①②③④⑤
Xiang et al[55]	32/33	24.2 ± 3.3	25.1 ± 3.4	22.9 ± 1.8	22.0 ± 1.3	JPSX + OI	OI	4 wk	①②③④⑦
Su et al[56]	30/30	26.8 ± 3.7	27.4 ± 4.2	22.6 ± 6.6	21.6 ± 6.0	JPSX + OI	OI	2 months	①②③④
Li et al[57]	48/48	27.36 ± 1.23	27.38 ± 1.26	18.53 ± 1.35	18.57 ± 1.38	JPSX + OI	OI	4 wk	①②③④
Wen et al[58]	60/60	26.6 ± 4.5	29.3 ± 2.6	22.8 ± 4.1	21.4 ± 3.1	YQBX + OI	OI	4 wk	③④⑤⑥
Liu et al[59]	40/40	28.6 ± 4.3	27.4 ± 3.2	23.8 ± 2.2	24.2 ± 2.1	YQBX + OI	OI	8 wk	①②③④⑥⑦
Luo et al[60]	50/50	28.3 ± 12.5	28.5 ± 12.4	21 ± 5	22 ± 4	YQBX + OI	OI	1 month	②③⑦
Jiang et al[61]	54/54	27.65 ± 5.92	26.85 ± 5.65	23.46 ± 5.58	24.37 ± 5.66	FFHY + OI	OI	4 wk	①③④⑤⑦
Zhang et al[62]	47/47	28.49 ± 3.20	28.15 ± 2.98	19.52 ± 2.19	19.12 ± 2.13	FFHY + OI	OI	4 wk	②③④⑦

T: Test group; C: Control group; OI: Oral iron; SXB: Shengxuebao Mixture; SXN: Shengxianning Tablet; YQWX: Yiqi Weixue Chinese patent medicines; JPSX: Jianpi Shengxue Chinese patent medicines; YQBX: Yiqi Buxue Tablets; FFHY: Compound Hongyi Buxue Oral Liquid; ① Clinical effective rate; ② Red blood cell level; ③ Hemoglobin level; ④ Serum ferritin level; ⑤ Serum iron level; ⑥ Adverse pregnancy outcomes; ⑦ Adverse events.